兰德-Treatment-for-dementia_-Learning-from-breakthroughs-for-other-conditions_154页_2mb

Treatment for Dementia: Lessons from Other Conditions

Core Content

This report, commissioned by the UK Department of Health, examines medical breakthroughs in the treatment of four health conditions—HIV/AIDS, coronary heart disease, breast cancer, and Parkinson's disease—and explores how these insights can be applied to dementia research and innovation. The study is conducted by RAND Europe, a not-for-profit policy research organisation, and highlights the importance of a multidisciplinary, collaborative, and flexible approach to fostering innovation in the dementia field.

The report is structured into four main parts:

1. Study Context and Objectives – Describes the rationale behind the study and the conceptual framework used to understand breakthroughs.
2. Study Design and Methods – Details the methodology, including desk research and expert interviews, and outlines the selection criteria for the case studies.
3. Key Findings from the Case Studies – Summarises the main factors that contributed to breakthroughs in the four conditions.
4. Policy Considerations and Potential Areas for Action – Proposes actionable strategies and policy considerations based on the case study findings.

Main Messages from the Case Studies

The study identified four key factors that enabled breakthroughs in the treatment of the four conditions:

1. Commitment to Tackling the Science

• Accumulation of scientific knowledge (basic and applied) was crucial.
• A strong scientific foundation encouraged industry engagement and supported drug development and repurposing.
• Interdisciplinary collaboration and long-term research were essential for overcoming scientific bottlenecks.

2. Active and Committed Advocacy Community

• Advocacy played a significant role in prioritising diseases in policy agendas and ensuring political and financial support.
• Strong social movements, often involving patients, celebrities, and NGOs, helped drive research and innovation efforts.
• High-profile individuals and organisations can act as champions, increasing visibility and investment in the disease.

3. Flexible and Responsive Regulatory Environment

• Regulatory frameworks that support accelerated approvals, fast-tracking, and conditional licensing can incentivise pharmaceutical industry involvement.
• Supportive regulation can also act as a catalyst for innovation, even in early stages of research.
• Regulatory interventions like patent pools may be beneficial before significant scientific breakthroughs occur.

4. Coordinated Strategic Response and Multi-Sector Collaboration

• Coordination across sectors and stakeholders was vital for enabling large-scale and rapid research and innovation.
• Public–private partnerships (PPPs) were seen as a way to stimulate innovation, though challenges in governance, IP, and stakeholder incentives must be addressed.
• National and international collaborations, such as the NIHR Dementia Translational Research Collaboration and the MRC Dementias Platform UK, support this approach.

Applicability to Dementia

The report outlines how these four factors can be adapted to the dementia context:

1. Basic Science and Applied Research

• The lack of understanding of dementia's basic science is a major barrier to innovation.
• However, supporting basic science should not come at the expense of applied and clinical research.
• Diverse and interdisciplinary research communities, along with dedicated funding, are needed to address scientific bottlenecks.

2. Advocacy Movement

• Advocacy for dementia is growing but needs to be more coordinated and sustained.
• A nuanced approach to advocacy, including engagement with both UK and international stakeholders, is recommended.
• Patient and public involvement is critical for building a strong advocacy movement.

3. Regulatory Environment

• A flexible and responsive regulatory framework is essential to support innovation in dementia.
• Regulatory interventions such as open access models and patent pools may be useful even before major scientific advances are made.
• The UK should consider how to streamline clinical trials and support industry engagement through appropriate legal and commercial incentives.

4. Strategic Collaboration

• Dementia research requires a coordinated national and global effort, with a clear strategy and monitoring framework.
• Multi-sector and interdisciplinary collaboration is necessary to address the complex challenges of dementia.
• PPP models and open innovation approaches can help diversify research and encourage experimentation.

Key Policy Considerations and Areas for Action

The report suggests several policy action areas, including:

1. The Science Bottleneck and Barriers to Translation

• Interdisciplinary Research Community: Need for a coordinated and diverse research community.
• Understanding the Competitive Landscape: Assessing UK strengths and gaps in dementia research.
• Building Capacity: Training future researchers and supporting long-term career pipelines.
• Supporting Diversity: Ensuring funding and support for all aspects of dementia research, including prevention and social care.

2. A Multi-Pronged Policy Mix

• Value Chain Approach: Ensuring funding supports the entire research and innovation value chain.
• Incentives for Innovation: Supporting both new compound R&D and drug repurposing.
• Public Sector Role: Ensuring appropriate clinical trials infrastructure and supportive regulation.

3. The Role of Collaborations

• PPP Models: Learning from successful models like the Structural Genomics Consortium.
• Facilitating Collaboration: Using thematic networks, prize funds, and staff exchanges to encourage interdisciplinary work.
• Coordination vs. Collaboration: Balancing coordination with collaboration to avoid bureaucratic pitfalls.
• Monitoring and Evaluation: Establishing mechanisms to evaluate the effectiveness of dementia research strategies.

4. A Strong and Sustainable Advocacy Movement

• Champions: Identifying credible individuals and institutions to advocate for dementia research.
• Advocacy Borders: Considering international advocacy and training for new advocates.
• Social Media: Leveraging platforms for awareness, stigma reduction, and peer support.
• Patient and Public Involvement: Encouraging active participation in research and innovation initiatives.

5. Paving the Way for Supportive Regulation

• Regulatory Prioritisation: Engaging in broader consultations on regulatory enablers.
• IP Pooling: Encouraging industry participation in patent pools for shared research.
• Open Access: Exploring the role of open access in accelerating scientific progress.

Conclusion

The report concludes that while dementia research faces unique challenges, there are valuable lessons from other conditions that can inform policy and innovation strategies. These include the importance of scientific understanding, advocacy, regulatory support, and collaboration. The proposed action areas aim to stimulate discussion and guide future policy development to address the dementia challenge effectively.